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ABSTRACT 
Introduction  
Mycobacterium tuberculosis meningitis (TBM) is a severe manifestation of extra-
pulmonary tuberculosis (EPTB) in children, particularly under 5 years of age. Children 
are vulnerable to EPTB as they are immunologically immature and unable to contain 
Mycobacterium tuberculosis (MTB) infection in the lung. Common neurological sequelae 
of TBM include focal motor deficits, vision loss and hydrocephalus. Early stage 
diagnosis and timeous anti-tuberculosis treatment decreases the case fatality rate of 
TBM. 
 
Objective  
To characterise the burden, clinical presentation, laboratory markers and short-term 
outcome of TBM in HIV-infected and HIV-uninfected children. 
 
Methods  
The electronic databases of admission of children at Chris Hani Baragwanath Academic 
Hospital (CHBAH), between January 2006 and December 2011 with a diagnosis of TBM 
were reviewed. Individual patient records were retrospectively reviewed for clinical and 
laboratory data. In addition, admissions from the neurosurgery wards were also 
reviewed. In patients whose medical records were unavailable, laboratory data was 
used. 
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Results  
The overall incidence of TBM in 2006 was 6.96 per 100 000 (95% Confidence Interval 
[95%CI]: 4.46-10.36), peaked at 9.87 per 100 000 (95% CI: 6.91-13.67) in 2009 and 
subsequently declined to 3.18 per 100 000 by 2011 (95% CI: 1.64-5.56). There was a 
38.6% (95% CI: 10.0-58.0; p=0.011) reduction in the overall incidence of TBM when 
comparing the period 2006-2009 with the period 2010-2011. This decline was 
particularly evident in HIV-infected children (49.6% reduction; 95%CI: 1.05-74.35; 
p=0.042). 
 
There were no differences in the clinical symptoms of TBM or tuberculosis between 
HIV-infected and -uninfected children. Previous history of TB was significantly higher in 
HIV-infected children compared to HIV-uninfected children (OR 4.63; 1.40-15.22; 
p=0.011). Tuberculin skin test positive-reactivity (OR 0.09; 0.02-0.43; p=0.002) and 
sputum culture positivity (OR 0.29; 0.10-0.86; p=0.025) were less common in HIV-
infected compared to -uninfected children. Cerebrospinal fluid cytology and 
biochemistry results were similar between HIV-infected compared to -uninfected 
children. Morbidity (22.7% in HIV-infected vs. 33.0% in -uninfected) and mortality (6.4% 
in HIV-infected vs. 6.9% in -uninfected) were similar between HIV-infected and -
uninfected children.  
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Conclusion 
The incidence of TBM has decreased over the study period 2006 to 2011.This decrease 
was temporally associated with an increase in the uptake of antiretroviral treatment in 
HIV-infected individuals.  
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1.0 INTRODUCTION  
1.1 Background 
An estimated one-third of the world’s population is infected with Mycobacterium 
tuberculosis (MTB) (1). The burden of tuberculosis (TB) mainly affects low-income 
countries particularly in Asia and Sub-Saharan Africa (2, 3). Of all childhood TB cases, 
75% occur among the 22 highest burdened countries, South Africa being one of them 
(4-6). Paediatric TB cases in South Africa account for approximately 15% of all TB 
cases in the country (6). Human Immunodeficiency Virus (HIV) infection has contributed 
significantly to the increased incidence of TB in countries where both HIV and TB are 
endemic. In 2012, approximately 1.1 million (13%) of the 8.6 million TB cases were HIV-
infected, 75% of whom lived in Africa. HIV-infected children have increased risk of 
developing TB, as well as more rapid TB progression, suboptimal treatment response 
and an increased risk of recurrence (7). CD4+ cell count depletion enhances 
susceptibility to TB (8, 9); whilst TB co-infection may promote HIV viral replication 
which, in turn, further decreases CD4+ cells counts (10). The risk of developing extra-
pulmonary tuberculosis (EPTB) is increased 17-fold in HIV-infected individuals, 
especially in those with low CD4+ counts (11-14). 
 
Tuberculosis meningitis (TBM) is a severe manifestation of EPTB in children (11, 15), 
particularly those under 5 years of age (16). Children may be vulnerable to 
disseminated TB, possibly due to an immature immune system, predisposing to being 
unable to contain the MTB infection to the lung (17). MTB reaches the central nervous 
system (CNS) through the haematogenous route. Granulomas are produced in the 
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meninges and adjacent brain parenchyma (Rich focus). Tuberculosis meningitis 
develops when the Rich focus ruptures and its contents spill into the subarachnoid 
space, (12) possibly due to a decrease in host-immunity (17). Following rupture, thick 
gelatinous exudates form in the basilar region of the brain which may block CSF flow 
resulting in hydrocephalus. Intracranial vessels may also get trapped within the 
exudates causing cerebral infarction and/or cranial nerve entrapment leading to cranial 
nerve palsies. The resulting inflammation presents clinically with varying degrees of 
encephalopathy (12). Common neurological sequelae of TBM include hemiplegia, 
quadriplegia, cognitive impairment, seizures and cranial nerve palsies in 25%-56% of 
survivors (9, 18-20).Mortality is about 30% (21). Early diagnosis and treatment have 
been proven to significantly reduce the risk of developing complications and mortality 
(19, 22). Signs of TBM are often nonspecific and similar to other bacterial causes of 
meningitis. 
 
Signs and symptoms suggestive of TBM are divided into 3 stages. Stage 1 is non-
specific features such as personality change, irritability, anorexia, listlessness and fever 
as a result of meningeal inflammation. Stage 2 presents 1 to 2 weeks later with features 
of increased intracranial pressure and neurological signs and symptoms such as 
drowsiness, neck stiffness, cranial nerve palsies, vomiting and focal or generalized 
convulsions (23). Stage 3 is associated with severe neurological deficits such as coma, 
autonomic instability and a rising fever (17). The long-term neurological morbidity in 
children with TBM is reported to correlate to the clinical stage of the disease at 
presentation and the timeliness of anti-TB therapy. The majority (11-61%) of children 
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with stage 1 TBM have a normal outcome, whereas stage 3 is associated with high 
case fatality rates (7-57%) and severe neurological sequelae (34-94%) among survivors 
(24, 24). Motor deficits are observed in 10-25% of children (17, 25). Furthermore, risk 
factors associated with poor outcome include a young age (<12 months), malnutrition, 
and an elevated intracranial pressure (17). 
 
The clinical diagnosis of TB requires a high index of suspicion in children. Signs and 
symptoms of TB may include low grade fever, a chronic cough and poor weight gain 
(23). These clinical features are supported by a reactive tuberculin skin test (TST) and 
radiological evidence suggestive of TB. The tuberculin skin test (TST) measures the 
type IV delayed hypersensitivity response to a purified protein derivative (7). The WHO 
recognises “definite case of tuberculosis” when MTB complex (M. tuberculosis, M. 
bovis, M. africanum, M. bovis BCG strain, M. pinnipedii, M. microti, M. caprae and M. 
canettii) is identified from a patient sample (26).  
 
The diagnosis of TBM remains challenging as signs and symptoms are non-specific and 
may overlap with that of other bacterial meningitis (15). Culture of CSF for MTB is the 
gold standard and studies have reported variable sensitivities (10% to >80%), which 
may be improved by increasing cerebrospinal fluid (CSF) volume analyzed, thorough 
microscopic examination and multiple samples being examined (11,12,27). Smear 
sensitivity on CSF for MTB is less than 10%, (11,12,28) and this is influenced by the 
volume of CSF collected (ideally 10- 20mls of CSF is required). In the absence of 
bacteriological confirmation of TBM, a typical CSF biochemical and cell profile includes 
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lymphocyte predominance, high protein, low glucose and low chloride (11,12,23). In 
addition to CSF findings, a history of TB contacts, a positive TST, suggestive CXR for 
pulmonary TB and brain CT scans are adjunctive tools used for clinically diagnosing 
TBM (17). 
 
 HIV associated TBM has both diagnostic and therapeutic challenges (27), coupled with 
a variable in-hospital case fatality rate in adult patients (63% vs. 18%; OR 7.4:95% CI 
3.0-18.5, p=0.000) (29) and when compared to another study showed no difference (27, 
30). Exudates in HIV-infected compared to HIV-uninfected adults are minimal, thinner 
and serous in nature. They contain fewer lymphocytes and epithelial cells (10,31), 
making the diagnosis more challenging (23). Computed Tomography (CT) scan of the 
brain in HIV-infected TBM cases shows features that are less specific, with 
hydrocephalus being uncommon, and ventricular dilatation being secondary to cerebral 
atrophy from HIV-infection, (10,23) resulting in an atypical radiological presentation of 
TBM in HIV-infected individuals,  which could lead to delayed or missed diagnosis and 
delayed treatment initiation. 
 
The Bacille Calmette-Guérin (BCG) vaccination provides protection against severe 
forms of TB such as TBM (64%) (32). It is a live attenuated form of Mycobacterium 
bovis. An estimated 90-94% BCG vaccine coverage was reported in 2009 and 2010 in 
South Africa (33). There is no significant difference in BCG- vaccinated and -
unvaccinated children with respect to clinical presentation, outcome and CT scan 
findings in children with TBM (34,35). In the South African setting all children including 
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those born to HIV-infected mothers, receive the BCG vaccination (16). There is limited 
data on the effectiveness of BCG vaccination in preventing pulmonary TB (8,35,36).  
 
Adenosine deaminase (ADA) is an enzyme required for T lymphocyte proliferation and 
differentiation. It converts adenosine into ionosine. ADA is released by the activated T 
cells in response to the MTB bacilli (37,38). The ADA test fails to differentiate between 
TBM and bacterial meningitis when used alone (39), however, once bacterial meningitis 
has been ruled out, an ADA value above 9.5 µ/L improves the specificity for diagnosing 
TBM in adults (40) . Furthermore, among children, ADA between 1-4 µ/L (sensitivity 
>90% and specificity <80%) helped to exclude TBM, while a value > 8µ/L (sensitivity                
<59% and specificity >96%) aided in establishing the diagnosis of TBM (21). High CSF 
ADA values are non-specific and may also be raised in conditions such as lymphoma 
(32) . Therefore, even though values have been established, ADA does not always help 
in the diagnosis of TBM as levels may be increased in other conditions as well. 
 
1.2 Literature review  
The incidence of TBM in both HIV-infected and -uninfected children remains largely 
unknown in high HIV/TB burden areas. The possible reasons for this include the inability 
to confirm TBM on culture, the non-specific biochemical findings and the under reporting 
in resource constrained settings. 
 
In the pre-HAART era, a study conducted in the Western Cape by Berman et al. 
reported an incidence of TBM from 1985 to 1987 as 10 per 100 000 in children <15 
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years of age.  The incidence of notified TBM stratified by age was reported as 31.5, 
17.1, 4.8, 0.7 per 100 000 in children aged <1 year, 1-4 years, 5-9 and 10-14 years, 
respectively, (13) which was higher than that reported in other countries (0 per 100 000 
in France between 1980-1984; 2.4 per 100 000 in Columbia in 1984 in the 0-4 year age 
group)(13).This could have been an underestimate as not all cases may have been 
notified. Following this, Hesseling et al. reported an estimated population based 
incidence of culture-confirmed TB in HIV-infected and -uninfected children in the 
Western Cape, between 2004 and 2006, of which 11% (27 of 245) had TBM. Hesseling 
et al. estimated the incidence of TBM to being 120 per 100 000 (95% CI: 28-258) in 
HIV-infected children and 7.9 per 100 000 (95% CI: 5-11) in HIV-uninfected children 
(16). These estimates likely underestimated the incidence of TBM due to only reporting 
on culture confirmed cases and some possibly having been missed due to lack of 
referrals. Furthermore, those children with an unknown HIV status were classified as 
being HIV-uninfected, which may have further resulted in underestimating the incidence 
of TBM in HIV-infected children or an overestimation in HIV-uninfected children. 
Although Asian countries have a high burden of TB, the incidence of TBM in Hong Kong 
was only reported as 0.369 per 100 000 in the study period 1993 to 2000 (41). TBM is 
uncommon in high-income countries with an incidence of 0.155 per 100 000 cases 
across all age groups reported over a two year period in France (42).  
 
Three paediatric studies have compared the clinical presentation, biochemical and 
radiological features of TBM between HIV-infected and -uninfected children (22,23,28) 
(Table1). In these studies the mean age ranged from 34-38 months, among HIV-
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uninfected children compared to 23-39 months in HIV-infected children (22, 23, 28). 
Although non-specific to TBM, clinical differences observed between HIV-infected and -
uninfected children with TBM included greater frequency of lymphadenopathy, clubbing, 
hepato-splenomegaly and otorrhoea; all of which could have been attributable to the 
underlying HIV-infection (23). Also, HIV-infected children with TBM had lower 
haemoglobin (<8 gm/dl) (28), while significant reactivity of the tuberculin skin test (TST) 
was more common among HIV-uninfected children (22). These studies, however, had 
small numbers of HIV-infected children and there were very few (35.5% versus 20.8% 
(23); 10% versus 6.66% (22)) microbiologically confirmed cultures. In the study by Van 
der Wreet et al, including 56 HIV-infected and 34 HIV-uninfected children, CSF findings 
did not differ between the  groups and the frequency of culture confirmed MTB was 
35.5% in HIV-infected compared to 20.8% in HIV-uninfected children (OR=2.1;95% CI 
0.78-5.66). HIV infected children were more likely to have abnormal CXR with hilar 
lymphadenopathy (60.1%) compared to HIV-uninfected children (37.3%; OR=2.59; 95% 
CI 1.05-6.37). Brain CT scan findings such as obstructive hydrocephalus was 
significantly lower in HIV infected (72%) compared to HIV-uninfected children (97.9%; 
OR=0.06, 95% CI 0.01-0.49), similarly basal enhancement was significantly less 
common in HIV -infected children (37.5% vs. 71.4 %;) OR=0.24; 95% CI 0.08-0.70) 
(23). 
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Table1: Paediatric Studies comparing HIV-infected and HIV-uninfected children with Tuberculosis Meningitis (TBM) 
*Key: Yr: year, Mo: Months, HIV +: HIV infected, HIV-: HIV uninfected, Poly: Polymorphocytes, Lymph: Lymphocytes, OR: Odds ratio.
Author Yr 
No. Of 
cases 
Mean 
Age 
(mo) 
Method of 
Diagnosis 
CSF findings 
Radiological 
Findings 
Mortality 
Topley 
et al. 
(22) 
1998 
30 HIV - 
 
10 HIV+ 
HIV+ 
23.4 
 
HIV- 
38.7 
Culture or 
Combination of 
clinical, CSF findings 
and TB found at 
another site 
 
[MTB culture on 
CSF: 
HIV-: 2/30(6.7%) 
HIV+: 1/10(10.0%)] 
 HIV + HIV- 
p-
value 
 HIV+ HIV- 
p-
value 
HIV+ HIV- 
p-
value 
Mean Poly 
mm
3
 
18 50 NS Hydrocephalus 80% 63% NS 30% 0% 0.010 
Mean 
Lymphocytes 
mm
3
 
219 
 
13 NS 
Basal 
Enhancement. 
40% 53% NS    
Mean 
Protein 
g/dl 
4.5 
 
1.8 NS Tuberculoma 20% 27% NS    
Mean 
Glucose 
mmol/l 
2.0 2.0 NS 
Basal ganglia 
infarcts 
40% 30% NS    
 
 
   
Cerebral 
atrophy 
40% 17% NS    
                
Karande 
et al. 
(28) 
2005 
115 HIV - 
 
8 HIV+ 
HIV+ 
34.5 
 
HIV- 
67 
Based on a clinical 
case definition 
Cells 
>100 
mm
3
 
50% 43% 1.000 Hydrocephalus 50% 46% 0.168 12% 23% 0.779 
Protein          
>1g/dl 
50% 60% 0.815 
Basal 
Inflammation 
62% 77% 0.597    
    Tuberculoma 25% 22% 0.232    
    
Cerebral 
infarcts 
37% 44% 0.993    
                
        
OR 
(95%
CI) 
   
OR 
(95% 
CI) 
  
OR 
(95% 
CI) 
Van der 
Weer 
 et al. 
(23) 
2006 
34 HIV- 
 
56 HIV+ 
HIV+ 
39 
 
HIV- 
38 
Culture  positive or 
Combination of 
radiological and 
clinical findings 
 
 
[MTB culture on CSF 
and gastric 
aspirates: 
HIV+: 35.5% 
HIV-: 2.0% 
Mean 
Poly 
mm
3
 
46 51 
0.99 
(0.99-
1.00) 
Hydrocephalus 72% 97% 
0.06 
(0.01-
0.49) 
23% 0% 
35.6 
(1.98-
640.2) 
Mean 
Lymp 
mm
3
 
212 178 
1.00 
(0.00-
1.00) 
Infarcts 50% 40% 
1.47 
(0.54-
4.04) 
   
Mean 
Protein 
g/dl 
2.4 1.9 
1.08 
(0.88-
1.34) 
Basal 
Exudate 
37% 71% 
0.24 
(0.08-
0.70) 
   
Mean 
Glucose 
mmol/l 
2.7 2.0 
1.26 
(0.87-
1.83) 
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Of the three studies among HIV-infected children with TBM, one study used only clinical 
criteria for diagnosing TBM (28), (Table 1) while the other two used a combination of 
clinical and microbiological criteria (22, 23). Overall, these three paediatric studies 
showed no difference in CSF biochemistry and CSF cell count findings between HIV-
infected and -uninfected children (22, 23, 28) (Table 1). A study conducted among 214 
HIV-uninfected children demonstrated that most (80%) children display “typical” 
biochemistry (lymphocyte predominance, high protein, low glucose) findings on CSF 
(25) . 
 
Chest X-ray features varied between the three paediatric studies, with no difference in 
CXR features observed between HIV-infected and -uninfected children with TBM by 
Karande et al, (28), whereas more abnormalities on CXR’s of HIV-infected children 
compared to -uninfected children with TBM were reported in the other two studies 
(22,23). This could, however, been due to non-TB opportunistic and chronic lung 
conditions such as LIP (lymphocytic interstitial pneumonia) and bronchiectasis in HIV-
infected children (23). 
 
CT scan findings in TBM include hydrocephalus, basal meningeal enhancement, 
infarction and tuberculoma (27) .There is conflicting data as to whether the frequency of 
meningeal enhancement is less common in HIV-infected children not on HAART 
compared to HIV-uninfected children (22,23).Furthermore, obstructive hydrocephalus 
was observed to be less common in HIV-infected compared to -uninfected TBM cases 
by van der Wreet et al.  (23). Thus, the paucity of CT scan changes among HIV-infected 
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children with TBM may lead to delayed diagnosis, which could contribute to increased 
mortality (23).  
 
TBM was associated with a higher mortality in HIV-infected compared to -uninfected 
children, in the studies by Topley et al, (30% vs. 0%; p=0.01) (22) and by van der Wreet 
et al. (23% vs. 0%; OR 35.60; 95% CI 1.98-640.29) (23). Furthermore, Topley et al. 
reported that 52% of HIV-uninfected children were normal at 6 to 12 months compared 
to 0% of HIV-infected children (p=0.01) (22), and similarly van der Weert et al. reported 
complete recovery in 60% (33/55) of HIV-uninfected children compared to 29% (10/3%) 
of HIV-infected children (OR 0.28; 95% CI 0.11-0.69) (22). The study by Karande et al. 
reported that only 19% (22/115) of HIV-uninfected children and 37% (3/8) HIV-infected 
children made a complete recovery (28).  
 
Among adults with TBM, similar to paediatric patients, most studies did not identify 
clinical, CSF laboratory cell count or biochemistry differences between HIV-infected and 
-uninfected adults (43-45). Clinical features of TBM between HIV-infected and -
uninfected adults were similar (31,43,46) except that HIV-infected adults had more 
cognitive impairment (31). There were 2 adult studies that reported a significantly lower 
CSF protein and cell count in HIV-infected adults with TBM compared to HIV-uninfected 
adults (29,31) (Table 2). One of these studies showed that HIV-infected adults had 
decreased pleocytosis and protein compared to -uninfected adults (29), while another 
study that looked only at HIV-infected adults showed a neutrophil dominance (47).  
Adult studies also show that ventricular dilatation and infarction are more common in 
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HIV-infected patients (43), whereas meningeal enhancement and obstructive 
hydrocephalus are more common among HIV-uninfected adults (31) (Table 2). 
 
Adults who received Highly Active Antiretroviral Treatment (HAART) prior to, or who are 
started on HAART during treatment for TBM had lower mortality rates (2,48). The 
majority of adult studies also demonstrated a higher mortality (up to 63%) among HIV-
infected adults compared to 17.5%% in HIV-uninfected adults (29, 31). Two studies in 
adults with TBM, however, demonstrated a trend that surviving cases had fewer 
neurological sequelae among HIV-infected compared to HIV-uninfected adults (43,49) 
(Table 2). 
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Table2: Adult studies comparing HIV-infected and HIV-uninfected adults with Tuberculosis Meningitis (TBM) 
*Key: Yr: year, Mo: Months, HIV +: HIV infected, HIV-: HIV uninfected, CTB: CT brain, Hydroceph: Hydrocephalus
Author Year 
No. Of 
cases 
Age 
Yrs 
Method of 
Diagnosis 
CSF findings 
Radiological 
Findings 
Mortality 
Scutte,CM 
(43) 
2001 
20 HIV+ 
 
17 HIV- 
 
Definite: Culture 
positive 
Probable: TB at 
another site and 
clinical, and laboratory 
features of  TB, and 
improvement on TB 
treatment 
 HIV + HIV- p-value  HIV+ HIV- p-value HIV+ HIV- p-value 
Mean 
Poly 
mm
3
 
69 87 0.62 
Abnormal 
CTB 
79% 75% 0.780 40% 41% 0.900 
Mean 
Lymph 
mm
3
 
164 96 0.07 Hydroceph 50% 35% 0.370    
Mean 
Protein 
g/dl 
2.88 3.47 0.51 Infarcts 40% 6% 0.010    
Mean 
Glucose 
mmol/l 
1.90 1.70 0.66        
ADA (µ/L) 12.60 13.50 0.67        
                
Cecchini,D 
(29) 
2008 
101 
HIV+ 
 
40 HIV - 
Median 
33  
MTB isolated on CSF 
culture 
Cell count 
Cells/ml 
47 167 0.02        
Pleocytosis
(%>4 cells 
/ml) 
80% 85.2% <0.001        
Mean 
Protein 
g/l 
0.77 1.15 0.01        
Mean 
Glucose 
mg/dl 
28 23 0.170        
                
Katrak,SM 
(31) 
 
2000 
22 HIV+ 
 
31 HIV- 
Median: 
HIV + 
33 
HIV – 
33 
Definite: 
Culture confirmed 
 
Highly probable: 
laboratory, 
improvement on TB 
treatment, TB form 
another site 
Probable: 
above criteria not met 
WCC 
(×10
/-3 
/ul) 
0.14 0.2 0.03 
Basal 
exudate 
33% 81% 0.002 36% 9% 0.03 
Mean 
Protein 
g/l 
1.24 1.75 0.01 Hydroceph 5.5% 63% <0.001    
Mean 
Glucose 
mmol/l 
0.46 0.50 NS Infarcts 38% 40% NS    
AFB + (%) 1 3 NS        
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This study, conducted in partial fulfilment of a Masters of Medicine in Paediatrics 
(MMed) degree, aims to determine the impact of childhood HIV-infection and changes in 
management thereof on the epidemiology of TBM in Soweto, South Africa. A 
retrospective review of clinical and laboratory records of children admitted with TBM to 
Chris Hani Baragwanath Hospital (CHBH) was undertaken.  
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1.3 Hypothesis and objectives 
The aim of this study was to describe the epidemiology, including incidence trends of 
TBM, associated with improved access to HAART for HIV-infected individuals, in a 
setting with a high prevalence of paediatric HIV-infection. 
 
Primary objective:  
 To determine temporal changes in the incidence of TBM in HIV-infected and HIV-
uninfected children between 2006 to 2011.  
Secondary objective:  
 To compare the clinical and laboratory characteristics of TBM between HIV-
infected and HIV-uninfected children 
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2.0 STUDY DESIGN AND METHODS 
2.1 Study design  
 A retrospective, descriptive study of the incidence and clinical findings of culture-
confirmed and all-categories of TBM in HIV-infected and HIV-uninfected children was 
undertaken for the period January 2006 to December 2011 at Chris Hani Baragwanath 
Academic Hospital (CHBAH). 
 
2.2 TBM definition 
Cases in the study were classified as confirmed, probable or possible TBM based on 
criteria (see Table 3). Patients who did not fit the criteria of confirmed, probable or 
possible, due to incomplete records, below were labelled as “undefined”. These patients 
were included in all the analysis. In addition, the undefined group were extrapolated into 
the confirmed, probable and possible group based on the percentage of these groups to 
the overall TBM. 
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Table 3: Adapted diagnostic criteria used by van Well and van der Weert (23,50) to 
diagnose Tuberculosis Meningitis (TBM) 
 
Confirmed TBM Probable TBM Possible TBM 
 
Mycobacterium tuberculosis  
identified on CSF culture 
 
Signs and symptoms of 
meningitis and 
 
Suggestive CSF finding : 
lymphocytosis, elevated 
protein, low glucose(all of 
these) and 
 
2 or more of the following 
-Poor weight gain 
-Household contact  with 
sputum smear-positive 
tuberculosis 
-CT scan compatible with 
TBM 
-Chest radiograph 
compatible with 
TB 
-Positive tuberculin skin test* 
-Other clinical specimens 
positive for AFB 
 
 
Patients who were treated 
empirically without fulfilling the 
criteria for confirmed or 
probable TBM 
*The TST is performed by injecting 0.1ml of PPD on the left anterior forearm and is read 48 to 72 hours 
later (i.e. Mantoux method). A positive skin reaction is measured by the transverse diameter of the 
induration and this is indicative of MTB infection. A positive response is indicated by a diameter of ≥10mm 
in an HIV-uninfected child and a diameter of ≥5mm in an HIV-infected or severely malnourished child (6). 
However, any reaction in HIV-infected children is usually considered as significant in this setting. A positive 
TST does not differentiate infection from disease (6). 
 
2.3 Study population  
Chris Hani Baragwanath Academic Hospital (CHBAH) is situated in Soweto, south of 
Johannesburg and is the only public hospital serving this area. It serves a population of 
approximately 1.4 million mainly black Africans, including 398 555 children under 15 
years of age (51). The area falls under Region D of the Johannesburg metropolis. 
Medical treatment, including anti-retrovirals and anti-TB drugs is provided for free to all 
children attending public health care facilities. It is estimated that 90% of all 
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hospitalisations involving individuals from Soweto would occur at CHBAH, the only 
public-hospital in the area. 
 
HIV prevalence and management in study population  
The prevalence of HIV in Gauteng was estimated to be 18-19% in adults and 4-5% in 
children during the study period (52). It is estimated that about 65% of the children who 
were eligible for HAART were on treatment in 2006 in this province compared to 96% in 
2011 (52) (Figure 1) 
 
 
Figure 1: Highly Active Antiretroviral Treatment (HAART) coverage in children age 0-14 years, 
across study period 2006-2011 in Gauteng, in whom HAART was required (52) 
 
During the study period, the criteria for initiating children on HAART included either 
recurrent admissions/ prolonged hospital-admissions or WHO stage 3 or 4 disease or if 
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clinically asymptomatic a CD4 count of <20% in children less than 18 months or <15% 
in those >18 months age. The first line HAART regimen in children less than 3 years of 
age included lamivudine, stavudine and lopinavir/ritonavir and lopinavir/ritonavir was 
substituted for efavirenz in older children (53). 
 
In 2010 the ART-management guidelines were amended in which Abacavir replaced 
Stavudine as one of the first line anti-retroviral treatments. The eligibility criteria for 
initiating HAART was changed so enable all children <1 year of age to be initiated 
immediately on HAART upon confirmation of being HIV-infected, as well as children 
between 1-5 years with a WHO stage 3 / 4 or CD4 count< 25% (or CD4 count <750 
cells/ mm3) and children older than 5 years with a WHO stage 3 /4 or a CD4 count of 
<350 cells/mm3 (54). 
 
The prevention of mother to child transmission programme (PMTCT) started in South 
Africa in 2001 as a pilot programme in a few selected areas with national 
implementation in 2004 (55). This initial programme included single doses of nevirapine 
to the mother during labour and to the newborn following delivery (55). This was 
changed in 2004 whereby mothers with CD4+ counts <200 cells/mm3 or WHO stage 4 
disease irrespective of CD4 count received HAART during pregnancy and those with 
CD4+ counts >200 cells/mm3 received nevirapine during labour. Additionally, newborns 
of HIV-infected mothers received nevirapine post-delivery (56). In April 2008 the 
PMTCT programme was further modified with mothers with CD4+ counts <200 
cells/mm3 being recommended to receive HAART and those with CD4+ >200 cells/mm3 
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recommended to receive zidovudine (AZT) daily during the pregnancy from 28 weeks. 
Furthermore, it was recommended that the mother also receives a single dose of 
nevirapine during delivery and AZT at the onset of labour and on a 3 hourly basis during 
labour. In addition, recommendations for the HIV-exposed newborn included a single 
dose of nevirapine at delivery and zidovudine twice daily for 7days or 28 days in 
mothers who received either greater or less than four weeks of antiretroviral treatment 
respectively (55). In 2010, all HIV-infected females with a CD4 < 350 cell/ mm3 or a 
WHO stage 3 or 4 disease received HAART during pregnancy. Those with a CD4 count 
of > 350 cell/ mm3  received AZT from 14 weeks with a single dose of NVP and AZT 3 
hourly during labour with a  single dose of tenofavir and FTC after  delivery (57) .In 
addition, AZT is discontinued in the newborns, and replaced this with nevirapine from 
birth to six weeks of life if the mom was on HAART or chose to use formula feed for her 
child and continued  as long as the mother continued to breastfeed and was not on 
HAART (54). All babies born in Soweto receive the BCG vaccination at birth irrespective 
of maternal HIV-infection status. 
 
Laboratory Methods 
Laboratory methods used by the National Health Laboratory Service (NHLS) for 
culturing MTB, include CSF being processed using the N-acetyl-L-cysteine-NaOH 
method. From 2006 onwards the BACTEC™ MGIT 960™ TB System (Mycobacterium 
Growth Indicator Tube) (Becton Dickinson, Sparks, Maryland) was used. 
The CSF cell counts were done using the Fuchs-Rosenthal counting chamber. Protein, 
glucose and chloride are measured as part of the CSF chemistry profile which use the 
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Roche Modular® and Cobas® 8000 (Roche Diagnostics, North America, USA) 
analysers. This is an automated system that utilises reagent specific kits. Typical CSF 
features of TBM in both adults and children include a leucocytosis of 10-1000 ˟ 106 
cells/l, predominantly lymphocytes. An elevated protein of >0.5g/l and a decreased CSF 
glucose to blood ratio of <0.5 is suggestive of TBM (27).  
 
CSF ADA was measured on the Cobas Mira® analyser (Roche Diagnostics, North 
America, USA) using the kit from (Diazyme® Laboratoriess, Poway, USA). It is based on 
the deamination of adenosine to ionosine. Ionosine is then converted to hypoxanine by 
PNP (purine nucleoside phosphorylase) . The amount of adenosine that generates one 
µmol of ionosine equates to one unit of ADA (58). 
 
CT scan and Chest X-ray findings were based on information documented in the 
patients medical records, with CXRs generally having been interpreted by the attending 
clinicians and brain CT scan by radiologists. 
 
The management of TBM at CHBAH included treatment with 4 drugs for 6 months 
[rifampacin (15-20mg/kg); Isoniazid (15-20mg/kg), Pyrazinamide (30-40mg/kg) and 
Ethionamide (15-20mg/kg)]. In addition prednisone is given at 2mg/kg for 4 weeks and 
then tapered over 2 weeks (6). INH prophylaxis has not been part of the national TB 
guidelines until 2013. 
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2.4 Study method 
A record review of all children admitted to general paediatric wards at CHBAH, with a 
discharge diagnosis of TBM, between January 2006 and December 2011 was analysed. 
Cases were identified from an electronic database of paediatric hospitalisations at 
CHBAH. These were cross referenced with TB notification books and records from the 
TB centre database. The TB centre database maintains a record of all children notified 
to have been initiated on TB treatment at CHBAH. Additionally, TBM cases managed in 
the neurosurgery wards were also identified from admission registries in these wards. 
Available subject medical-records were reviewed and clinical information extracted. 
Laboratory data was retrieved from the NHLS database on all patients, including those 
whose medical records were unavailable. Children with a positive bacterial culture on 
CSF other than MTB were excluded from the study. Children referred from other 
hospitals and not resident in Soweto, as well as those who started TBM treatment 
outside of the study period were excluded (Figure 2). 
 
Approval to conduct the study at CHBAH was obtained from the Medical Advisory 
Committee at the hospital and the Human Research Ethics Committee (HREC) at the 
University of Witwatersrand (HREC number: M120542).  
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28 children were excluded 
(Referred from other hospitals;  
Diagnosis other than TBM;  
Diagnosed with TBM outside the 
study period) 
                                                                           
 
 
 
 
 
 
 
                                                                                                                                     
 
 
                                         
 
 
 
                            The following children were excluded: 
                                  1) Children referred from another hospital (N=20) 
                                *2) Diagnosed with TBM out of the study period (N=6)                             
                                
$
3) Children incorrectly captures as TBM on database (N=10)     
                                 4) Patients notified as extracranial TB (N=8) 
                                 5) Duplicates (N=10)                                        
                                                                   
 
 
 
 
 
                                  
 
 
 
Figure 2: Schematic representation of study methods used to collect data in children with 
Tuberculosis meningitis (TBM) 
*TBM reflected in the discharge summary however patient started on TBM treatment prior to study period 
$
TBM diagnosis incorrectly reflected on the discharge summary and database 
†
These 5 cases were captured as bacterial meningitis on the database, but were TBM  
 
Paediatric database that included a discharge 
diagnosis of meningitis 
N= 4452 
ICD 10 codes 
for meningitis 
A86,A87,B05,G00.0 
G00.1,G002.2,G00.9
G03.9,G04.2,G40.6,
G40.9,G41.9,G80.8,
G91.9,R56.0 
Children from neurosurgical 
ward 
N=43 
TOTAL CHILDREN REVIEWED 
WITH medical records available 
N=96 
 
 
TOTAL NUMBER OF CHILDREN REVIEWED 
N= 197 
TOTAL CHILDREN WITH NO medical records, 
in whom DATA EXTRACTED FROM 
ELECTRONIC DATABASE AND NHLS N=47 
 
 
TOTAL NUMBER OF CHILDREN ANALYSED N=143 
ICD10 codes 
for TBM 
A17.0, G01, A17.1, 
A17.8. A19.1, R90.0 
 
N=5
†
 
 
N=177 N=15 
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2.5 Statistical Analysis 
Estimated incidence of TBM were calculated and stratified by HIV-infection status to 
yield stratum specific incidence. Due to a low percentage (8 of 143, 5.6%) of culture-
confirmed cases, all categories of TBM were combined for the incidence estimates. 
 
The numerator for incidence calculation were the number of TBM episodes hospitalised 
during each year and the denominator was based on mid-year population estimates 
from the Gauteng Department of Health and Social development for region D (Soweto) 
in Johannesburg as per the Statistics South Africa report (51) (Table 4). HIV prevalence 
in the study population between the years 2006 to 2011 was estimated from the 
projections of the Gauteng- Sub-district Population Mid-year Estimates 2005-2012 (52) 
(Table 4). 
 
To compare the differences between HIV-infected and -uninfected children, odds ratios 
were used for categorical variables. Continuous variables such as CSF and blood 
results were analysed using Mann Whitney U tests as the data was not normally 
distributed. A 95% confidence intervals for parameters of interest were reported and p-
values<0.05 were considered statistically significant. STATISTICA version 12 SP2   
(statsoft.com) and STATA version 10.0 (College Station, Texas, USA) was used for 
data analysis and to calculate the confidence intervals, risk ratios and incidences of 
TBM. 
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Table 4: Population denominators and HIV prevalence by age-group in Soweto 
(Region D, Johannesburg), South Africa1,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Population estimates for region D (Soweto) in Johannesburg as per Statistics South Africa (51) 
2HIV prevalence in the study population was estimated from the projections of the AIDS and   
Demographic models developed by the Actuarial Society of South Africa (52) 
 
 
 
 
 
Year 
 
Age 
Total 
population1 
 
HIV prevalence2 
    
2006 0 - 1 years 22382 5.7% 
 
1 – 4 years 96797 3.9% 
 
5 -14 years 225563 1.2% 
    
2007 0- 1 years 21326 5.2% 
 
1- 4 years 95807 4.1% 
 
5 -14 years 234353 1.5% 
    
2008 0 - 1 years 21077 4.6% 
 
1 – 4 years 95198 4.1% 
 
5 -14 years 241801 1.8% 
    
2009 0 - 1 years 21627 4.0% 
 
1 – 4 years 95152 4.2% 
 
5 -14 years 247918 2.0% 
    
2010 0 - 1 years 22660 3.9% 
 
1 – 4 years 95773 3.9% 
 
5 -14 years 252732 2.3% 
    
2011 0 - 1 years 23777 3.9% 
 
1 – 4 years 96887 3.7% 
 
5 -14 years 256627 2.5% 
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3.0 RESULTS 
3.1 Demographic information of all children hospitalised with all categories of 
TBM between 2006 and 2011 
A total of 143 TBM cases were identified for the period 2006 to 2011, including 74 
(51%) males and 69 (49%) females (Table 5). The overall median age was 3.7 years 
(range 0.07-14.18) and the majority of children were underweight for age with a median 
z-score of -2.25 (range -5.68 to 1.93). Forty-seven (32.9%) of the children were HIV-
infected, whilst HIV-infection status was unknown among 9 (6.3%) children. CD4+ cell 
counts were obtained in 43 of the 47 (91%) HIV-infected children, of which 30 (69.8%) 
were categorised as severely immunocompromised based on the WHO immunological 
classification of HIV (Table 5). 
  
Culture of MTB on CSF was requested in 50 of 143 (35.0%) TBM cases, of which MTB 
was cultured in 8 cases (16.0% of 50; or 5.6% of overall TBM cases). A further 46 
(32.1%) children were classified as probable TBM, 48 (33.6%) as possible TBM and 
41(28.7%) were undefined (Table 5).  
 
Demographic data was further analysed by combining the confirmed and probable TBM 
cases. Similar median ages and weight for age z-scores were noted compared to all 
TBM cases (Table 6). Children with possible TBM, however, tended to be older (median 
5.95) and less malnourished (median weight for age z-score of -1.2) compared to HIV-
uninfected children (Table 7).
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Table 5: Demographic information of children hospitalised with all categories of Tuberculosis meningitis  (TBM) 
between 2006 and 2011 
 
Year 2006 2007 2008 2009 2010 2011 Overall 
Total no. of cases 24 22 26 36 23 12 143 
Confirmed 1(4.2%) 0(0%) 2(7.7%) 4(11.1%) 1(4.4%) 0(0%) 8(5.6%) 
Probable 12(50%) 9(40.9%) 6(23.1%) 11(30.6%) 6(26.1%) 2(16.6%) 46(32.2%) 
Possible 5(20.8%) 8(36.4%) 11(42.3%) 12(33.3%) 7(30.4%) 5(41.7%) 48(33.6%) 
Undefined 6(25%) 5(22.7%) 7(26.9%) 9(25%) 9(39.1%) 5(41.7%) 41(28.6%) 
        
HIV-infected 7(29.2%) 9(40.9%) 10(38.5%) 10(27.8%) 7(30.4%) 4(33.3%) 47(32.9%) 
HIV-uninfected 17(70.8%) 12(54.5%) 13(50.0%) 22(61.1%) 15(65.2%) 8(66.7%) 87(60.8%) 
HIV-unknown 0 1(4.6%) 3(11.5%) 4(11.1%) 1(4.4%) 0 9(6.3%) 
        
Age (%)        
Median(years) 3.17 2.7 3.89 5.47 5.16 4.3 3.70 
Range(years) 0.13-10.79 0.57-14.18 0.29-12.9 0.08-11.63 0.53-12.48 0.4-13.04 0.07-14.18 
<1 yr 4(16.6%) 2(9.1%) 5(19.2%) 6(16.7%) 1(4.3%) 3(25.0%) 21(14.7%) 
1-<5yrs 10(41.7%) 12(54.5%) 10(38.5%) 10(27.8%) 10(43.5%) 3(25.0%) 55(38.4%) 
5 - <15yrs 10(41.7%) 8(36.4%) 11(42.3%) 20(55.6%) 12(52.2%) 6(50.0%) 67(46.9%) 
        
Male Gender (%) 12(50%) 16(72.7%) 13(50.0%) 19(52.7%) 6(26%) 8(66.6%) 74(51.7%) 
        
Weight for Age (<10yrs) n=20 n=15 n=13 n=27 n=16 n=9 n=100 
Median Z-scores -2.41 -2.56 -1.70 -2.34 -1.77 -2.26 -2.25 
Range -5.68 to -0.08 -5.01 to 0.91 -3.75 to 1.93 -3.51 to 0.13 -4.75 to 0.68 -3.73 to-0.61 -5.68 to 1.93 
        
HIV-infected with CD4 n=5 n=8 n=9 n=10 n=7 n=4 n=43 
*Severe immunocompromised (%) 2/5(40.0%) 6/8(75.0%) 8/9(88.8%) 8/10(80.0%) 4/7(57.1%) 2/4(50.0%) 30(69.8%) 
  
*WHO Immunological classification for established HIV infection(CD4% or absolute number per mm3) (59) 
                                                Not significant Mild Advanced Severe*  
<11 months  >35% 30-35% 25-29% <25%  
12-35 months  >30% 25-30% 20-24% <20%  
36-59 months  >25% 20-25% 15-19% <15%  
>5yrs  >500 350-499 200-349 <200/<15%  
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Table 6: Demographic information of children hospitalised  with confirmed and probable Tuberculosis meningitis 
(TBM) between 2006 and 2011  
  
Year 2006 2007 2008 2009 2010 2011 Overall 
Total no. of cases        
Confirmed and Probable 13 9 8 15 7 2 54 
        
HIV-infected 5(38.5%) 4(44.4%) 4(50.0%) 4(26.7%) 4(57.1%) 0 21(38.9%) 
HIV-uninfected 8(61.5%) 5(55.6%) 4(50.0%) 8(53.3%) 3(42.9%) 2(100%) 30(55.6%) 
HIV-unknown 0 0 0 3(20.0%) 0 0 3(5.5%) 
        
Age (%)        
Median(years) 2.39 2.15 3.89 3.74 8.01 5.87 3.81 
Range(years) 0.27-8.58 0.86-11.69 0.7-12.91 0.17-10.72 1.13-12.03 5.74-6.16 0.17-12.91 
<1 yr 3(23.1%) 2(22.2%) 1(12.5%) 4(26.7%) 0 0 10(18.5%) 
1-<5yrs 7(53.8%) 3(33.3%) 4(50.0%) 4(26.7%) 2(28.6%) 0 20(37.1%) 
5 - <15yrs 3(23.1%) 4(44.5%) 3(37.5%) 7(46.6%) 5(71.4%) 2(100%) 24(44.4%) 
        
Male Gender(%) 8(61.5%) 6(66.6%) 5(62.5%) 9(60%) 1(14.2%) 0 29(53.7%) 
        
Weight for Age (<10yrs)        
Median Z-scores -2.68 -3.00 -2.38 -2.95 -3.18 -1.91 -2.81 
Range -5.68 to -0.87 -3.87 to -0.14 -3.75 to -1.64 -4.87 to -0.88 -4.75 to -0.66 -2.26 to -1.56 -5.68 to -0.14 
HIV-infected with CD4 n =4 n =4 n = 3 n = 4 n = 4 n =2 21 
*Severe immunocompromised(%) 2(50.0%) 3(75.0%) 2(66.0%) 2(50.0%) 2(50.0%) 0(0%) 11(52.3%) 
  
WHO immunological classification for established HIV infection(CD4% or absolute number per mm3) (59) 
                                                Not significant Mild Advanced Severe*  
<11 months  >35% 30-35% 25-29% <25%  
12-35 months  >30% 25-30% 20-24% <20%  
36-59 months  >25% 20-25% 15-19% <15%  
>5yrs  >500 350-499 200-349 <200/<15%  
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Table 7: Demographic information of children hospitalised with possible Tuberculosis meningitis (TBM) between 
2006 and 2011 
  
Year 2006 2007 2008 2009 2010 2011 Overall 
Total no. of cases        
Possible 5 8 11 12 7 5 48 
        
HIV-infected 1(20.0%) 3(37.5%) 4(36.4%) 4(33.3%) 3(42.9%) 2(40.0%) 17(35.4%) 
HIV-uninfected 4(80.0%) 5(62.5%) 5(45.5%) 8(66.7%) 4(57.1%) 3(60.0%) 29(60.4%) 
HIV-unknown 0 0 2(18.1%) 0 0 0 2(4.2%) 
        
Age (%)        
Median(years) 5.95 3.2 7.52 6.95 5.16 5.96 5.95 
Range(years) 1.22-10.94 1.2-13.20 0.46-11.42 0.38-11.63 0.53-12.48 1.28-9.61 0.46-13.20 
<1 yr 0 0 2(18.2%) 2(16.7%) 1(14.3%) 0 5(10.4%) 
1-<5yrs 1(20.0%) 6(75.0%) 3(27.3%) 1(8.3%) 2(28.5%) 2(40.0%) 15(31.3%) 
5 - <15yrs 4(80.0%) 2(25.0%) 6(54.5%) 9(75.0%) 4(57.2%) 3(60.0%) 28(58.3%) 
        
Male Gender(%) 1(20.0%) 6(75.0%) 6(54.5%) 7(58.3%) 0 4(80.0%) 24(50.0%) 
        
Weight for Age (<10yrs)        
Median Z-scores -1.19 -1.2 0.16 -1.84 -1.82 -1.44 -1.2 
Range -4.33 to -0.08 -2.56 to 0.91 -2.68 to 1.93 -4.77 to 0 -3.81 to 0.59 -3.55 to -0.61 -4.77 to 1.93 
HIV-infected with CD4 n =0 n =2 n = 4 n = 4 n =3 n =2 16 
*Severe immunocompromised(%) 0(0.0%) 1(50.0%) 4(100.0%) 4(100.0%) 3(100.0%) 1(50.0%) 13(81.3%) 
  
WHO immunological classification for established HIV infection(CD4% or absolute number per mm3) (59) 
                                                Not significant Mild Advanced Severe*  
<11 months  >35% 30-35% 25-29% <25%  
12-35 months  >30% 25-30% 20-24% <20%  
36-59 months  >25% 20-25% 15-19% <15%  
>5yrs  >500 350-499 200-349 <200/<15%  
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3.2 The Incidence of TBM in HIV-infected and HIV-uninfected children. 
The overall incidence (per 100 000) of TBM in 2006 was 6.96 (95%CI 4.46-10.36) and 
peaked in 2009 at 9.87 per 100 000 (95% CI: 6.91-13.60) (Figure 3).This was followed 
by decrease in 2010 and 2011. In HIV-infected children across all age groups, the 
incidence of TBM per 100 000 also trended to increase steadily from 89.35 (95% CI: 
35.93-184.02) in 2006 to 101.10 (95% CI: 48.49-185.80) in 2009 and subsequently 
declined in 2010 to 66.63 (95% CI: 26.80-137.70) and to 36.26 (95% CI: 9.88-92.81) in 
2011 (Figure 3). With regard to HIV-uninfected children, the incidence of TBM ranged 
from 5.05 (95% CI: 2.94 - 8.08) in 2006 to 2.19 (95% CI: 0.94-4.30) per 100 000 in 2011 
(Figure 3). 
 
The incidence for period 2006-2009 was compared to that in 2010-2011. The overall 
incidence (per 100 000) of TBM was 7.61 (95% CI: 6.24-9.19) in 2006-2009 and 4.68 
(95% CI: 3.26-6.50) in 2010-2011, with an overall reduction of 38.55% (95% CI: 10.04-
58.03; p=0.011) (Table 8). In HIV-infected children across all age groups the incidence 
of TBM in 2006-2009 was 101.43 (95% CI: 71.05-140.40) compared to 51.07 (95% CI: 
25.50-91.37) in 2010-2011, i.e. rate reduction of 49.6% (95% CI: 1.1-74.4; p=0.042) 
(Table 8). There was no significant reduction in TBM incidence in HIV-uninfected 
children comparing the period 2006-2009 (4.63) with 2010-2011 (31.60; p=0.116) (Table 
8).  
 
When analysing the composite of confirmed and probable TB cases between 2006-
2009 and comparing this to 2010-2011, a significant rate reduction of 62.08% (95% CI: 
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22.43-81.46; p=0.005) was observed overall, as well as in HIV-uninfected children   
(61.9%; 95% CI: 5.7-85.4; p=0.04), whereas no reduction was observed in HIV-infected 
children. The incidence of “possible” TBM did not change over the study periods 
(p=0.164) (Table 8).  
 
Furthermore, we conducted a sensitivity analysis to proportionately include the number 
of cases that were “undefined” into one of the above two mentioned groups based on 
the prevalence of confirmed/probable and possible TBM among those for whom it was 
known. The results were similar to that of the crude analysis, except that the reduction 
in the HIV-infected with confirmed/probable was now significant (95% CI: 20.85-75.27; 
p-value=0.004) (Table 8). 
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Figure 3: Yearly incidence of Tuberculosis meningitis (TBM) from 2006-2011 
stratified by HIV status 
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Table 8: Comparing the incidence of Tuberculosis meningitis (TBM) between 2006-
2009 to 2010-2011 
 2006-2009 2010-2011 
Comparing 2006-2009 
and 
2010- 2011 
IRRa 
p-value^ %Reduction# 
 
Incidence of TBM 
[95%CI] 
(N of TB cases) 
Incidence of TBM 
[95%CI] 
(N of TB cases) 
   
      
Overall TBM 7.61[6.24-9.19] 4.68[3.26-6.50] 0.61[0.41-0.89] 0.011 38.6[10.0-58.0] 
 108 35    
HIV-infected 101.43[71.05-140.40] 51.07[25.50-91.37] 0.50[0.25-0.98] 0.042 49.6[1.1-74.4] 
 36 11    
HIV-uninfected 4.63[3.56-5.19] 3.16[2.01-4.75] 0.68[0.42-1.10] 0.116 31.6[-10.1-57.5] 
 64 23    
      
Confirmed TB and 
Probable 
3.17[2.31-4.24] 1.20[0.55-2.28] 0.37[0.18-0.77] 0.005 62.1[22.4-81.5] 
 45 9    
HIV-infected 47.9[27.91-76.68] 18.57[5.06-47.55] 0.38[0.13-1.15] 0.076 61.2[-15.3-86.9] 
 17 4    
HIV-uninfected 1.81[1.17-2.67] 0.68[0.22-1.61] 0.38[0.14-0.99] 0.040 61.9[5.7-85.4] 
 25 5    
      
Possible TB 2.54[1.78-3.51] 1.60[0.82-2.80] 0.63[0.32-1.21] 0.164 36.8[-21.4-67.1] 
 36 12    
HIV-infected 33.81[17.47-59.05] 23.22[7.54-54.17] 0.68[0.24-1.94] 0.477 31.3[-94.9-75.8] 
 12 5    
HIV-uninfected 1.59[0.99-2.41] 0.96[0.87-1.98] 0.60[0.25-1.41] 0.242 39.4[-41.8-74.1] 
 22 7    
      
      
Confirmed and 
Probable TB 
extrapolated to 
include undefined 
14.23[3.23-5.44] 1.87[1.02-3.14] 0.44[0.24-0.79] 0.004 55.8[20.9-75.3] 
 60 14    
HIV-infected 59.17[36.63-90.43] 18.57[5.06-47.55] 0.31[0.10-0.91] 0.024 68.6[8.5-89.2] 
 21 4    
HIV-uninfected 24.58[17.02-34.34] 1.24[0.56-2.35] 0.50[0.24-1.05] 0.060 49.6[0.5-75.8] 
 34 9    
      
Possible TB 
extrapolated to 
include undefined 
3.38[2.49-4.48] 2.81[1.74-4.29] 0.82[0.49-1.38] 0.474 17.1[-38.5-50.3] 
 48 21    
HIV-infected 42.26[23.66-69.70] 32.5[13.07-66.96] 0.76[0.31-1.88] 0.565 23.1[-88.5-68.6] 
 15 7    
HIV-uninfected 2.17[1.46-3.10] 1.93[1.05-3.23] 0.88[0.47-1.67] 0.714 11.2[-67.5-52.9] 
 30 14    
*IRR=Incidence Risk Ratio (Population denominators were added for 2006 to 2009 and for 2010 to 2011 
^ χ² test or Fischer test 
#
%reduction between Early and Established HAART era 
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3.3 “Confirmed and probable” TBM stratified by age  
The incidence (per 100 000) of confirmed and probable TBM stratified by age was 
highest in children <1 year age from 2006 (13.40; 95% CI: 2.76-39.17) to 2009 (18.5; 
95%CI: 5.04-47.35), with no cases reported in 2010 and 2011 in this age group (Figure 
4). 
 
3.4 “Possible” TBM stratified by age  
There were no cases of possible TBM in the <1 year age group in 2006 and 2007, 
however in 2009 the incidence (per 100 000) was 9.25 (95% CI: 1.12-33.4) and 4.41 
(95% CI: 0.11-25) in 2010. In the 1-5 year age group, the highest incidence was noted 
in 2007 with 6.26 per 100 000 (95% CI: 2.30-13.63) and a decline was noted in 2009 of 
1.05 per 100 000 (95% CI: 0.02-5.86) (Figure 5). 
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Figure 4: Incidence of “confirmed and probable” Tuberculosis meningitis (TBM) 
from 2006-2011 stratified by age 
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Figure 5: Incidence of possible Tuberculosis meningitis (TBM)  from 2006-2011 
stratified by age 
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3.5 Clinical symptoms and signs in children with TBM 
Constitutional symptoms of TB, such as coughing, weight loss and night sweats were 
similar between HIV-infected and -uninfected children. The odds of having a previous 
history of TB was significantly higher among HIV-infected children compared to -
uninfected children (OR 4.63; 95%CI: 1.40-15.22; p= 0.011)(Table 9). TB exposure from 
family or household contact was present in 38.2% of HIV-infected and 22.4% of -
uninfected children (OR 2.95; 95%CI: 0.75-5.30; p= 0.163) (Table 9). 
 
Symptoms suggestive of meningitis such as headache, fever, neck pain, vomiting,  
photophobia and seizures were similar in both groups; with a high proportion of  
children presenting with fever (50.0% HIV-infected and 60.3% HIV-uninfected) and neck 
pain (58.8% HIV-infected and 55.2% HIV-uninfected) (Table 9 and 10). HIV-infected 
children presented less commonly with irritability (23.5%) compared with HIV-uninfected 
children (43.1%; OR 0.22; 95%CI: 0.07-0.71; p=0.010). Paralysis, seizures, hemiplegia, 
long tract signs (long tract signs: spasticity, hyper-reflexia and clonus associated with 
upper motor neuron pathology) and cranial nerves showed no significant difference 
between HIV-infected and -uninfected children. 
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Table 9: Clinical symptoms suggestive of tuberculosis in children with 
Tuberculosis meningitis (TBM)  n=92 
*Not recorded: No record of symptom in file 
˟TB exposure: Indicates household contacts 
 
 
 
Symptoms 
HIV-infected 
n=34 
HIV-uninfected 
n=58 
Odds Ratio p-value 
Cough 
(Any duration) 
    
Yes 20(58.9%) 26(44.8%) 2.11(0.58-7.64) 0.252 
No 4(11.7%) 11(19.0%)   
Not recorded* 10(29.4%) 21(36.2%)   
Night sweats     
Yes 3(8.8%) 2(3.4%) 2.50(0.25-24.72) 0.432 
No 3(8.8%) 5(8.6%)   
Not recorded 28(82.4%) 51(88.0%)   
Weight loss     
Yes 10(29.4%) 11(19.0%) 0.30(0.01-8.31) 0.480 
No 1(3.0%) 0   
Not recorded 23(67.6%) 47(81.0%)   
Loss of Appetite     
Yes 15(44.1%) 20(34.5%) 6.80(0.34-136.04) 0.209 
No 0 4(6.9%)   
Not recorded 19(55.9%) 34(58.6%)   
Previous history of 
TB 
    
Yes 11(32.4%) 5(8.6%) 4.63(1.40-15.22) 0.011 
No 19(55.9%) 40(69.0%)   
Not recorded 4(11.7%) 13(22.4%)   
TB exposure˟     
Yes 13(38.2%) 13(22.4%) 2.00(0.75-5.30) 0.163 
No 16(47.1%) 32(55.2%)   
Not recorded 5(14.7%) 13(22.4%)   
Vomiting     
Yes 13(38.2%) 19(32.8%) 1.07(0.40-2.84) 0.883 
No 14(41.2%) 22(37.9%)   
Not recorded 7(20.6%) 17(29.3%)   
Headache     
Yes 10(29.4%) 14(24.1%) 0.71(0.08-5.95) 0.755 
No 2(5.9%) 2(3.5%)   
Not recorded 22(64.7%) 42(72.4%)   
Neck pain     
Yes 20(58.8%) 32(55.2%) 0.97(0.35-2.66) 0.956 
No 9(26.5%) 14(24.1%)   
Not recorded 5(14.7%) 12(20.7%)   
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Table 10: Clinical signs suggestive of tuberculosis in children with Tuberculosis 
meningitis (TBM) n=92 
 
*Not recorded: No record of sign in file 
†
Long tract signs: spasticity, hyper-reflexia and clonus associated with upper motor neuron pathology 
 
 
 
 
 
Signs 
HIV-infected 
n=34 
HIV-uninfected 
n=58 
Odds Ratio p-value 
Fever     
Yes 17(50.0%) 35(60.3%) 0.7(0.27-1.84) 0.478 
No 11(32.4%) 16(27.6%)   
Not recorded* 6(17.6%) 7(12.1%)   
Confusion     
Yes 5(14.7%) 6(10.3%) 0.83(0.20-3.42) 0.800 
No 13(38.2%) 13(22.4%)   
Not recorded 16(47.1%) 39(67.3%)   
Irritability     
Yes 8(23.5%) 25(43.1%) 0.22(0.07-0.71) 0.010 
No 14(41.2%) 10(17.2%)   
Not recorded 12(35.3%) 23(39.7%)   
Drowsiness     
Yes 9(26.5%) 19(32.8%) 0.49(0.18-1.37) 0.177 
No 19(55.9%) 20(34.4%)   
Not recorded 6(17.6%) 19(32.8%)   
Photophobia     
Yes 5(14.7%) 4(6.9%) 1.56(0.31-7.13) 0.610 
No 10(29.4%) 12(20.7%)   
Not recorded 19(55.9%) 42(72.4%)   
Paralysis     
Yes 4(11.8%) 16(27.6%) 0.32(0.09-1.12) 0.070 
No 20(58.8%) 26(44.8%)   
Not recorded 10(29.4%) 16(27.6%)   
Seizures     
Yes 14(41.2%) 32(55.2%) 0.6(0.26-1.65) 0.370 
No 14(41.2%) 21(36.2%)   
Not recorded 6(17.6%) 5(8.6%)   
Hemiplegia     
Yes 2(5.9%) 12(20.7%) 0.22(0.04-1.09) 0.060 
No 32(94.1%) 44(75.9%)   
Not recorded 0 2(3.4%)   
Long tract signs
†
     
Yes 4(11.8%) 13(22.4%) 0.44(0.13-1.5) 0.190 
No 29(85.3%) 42(72.4%)   
Not recorded 1(2.9%) 3(5.2%)   
     
Cranial Nerve 
Palsy 
    
Yes 1(2.9%) 10(17.2%) 0.14(0.017-1.177) 0.070 
No 32(94.2%) 46(79.3%)   
Not recorded 1(2.9%) 2(3.5%)   
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3.6 Clinical, laboratory and brain CT scan investigations in children with TBM  
A high proportion of children’s TST results were not recorded (n=50/100; 50%). HIV-
infected children were less likely to have a reactive TST (11.1%) compared to HIV-
uninfected children (32.8%; p=0.002)(Table 11).There was also a lesser proportion of 
HIV-infected children (27.6%) who had positive sputum or gastric washing (including 
smear and/or culture) results for Mycobacterium tuberculosis compared to HIV-
uninfected TBM cases (12.8%; p=0.025). Brain CT scan findings such as tuberculoma, 
basal enhancement and infarcts were generally uncommon; but occurred more 
frequently in HIV-uninfected children. Notably, 5/19 (26.3%) of HIV-infected children had 
radiologic evidence of hydrocephalus compared with 27/55 (49.1%) of HIV-uninfected 
children, however this was not statistically significant (p= 0.096) (Table 11). 
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Table 11: Radiological and clinical investigations performed in children admitted 
with Tuberculosis Meningitis (TBM)  
*Not recorded: No record of symptom in file 
†Mantoux test- Purified Protein Derivative (PPD) tuberculin injected intra-dermally to asses for TB 
infection in children  
‡
Sputum-Mycobacterium tuberculosis cultured on sputum samples taken in children suspected to have 
TBM 
 
 
 
 
 
  
Investigation HIV-infected HIV-uninfected Odds ratio p-value 
Mantoux test
†
 n=36 n=64   
Reactive 4(11.1%) 21(32.8%) 0.09(0.02 -0.43) 0.002 
Non-reactive 10(27.8%) 15(23.4%)   
Not recorded* 22(61.1%) 28(43.8%)   
   
  
Chest X-ray n=34 n=58   
Suggestive of PTB 9(26.5%) 13(22.4%) 1.03(0.14 -7.52) 0.970 
Not suggestive of PTB 2(5.9%) 3(5.2%)   
Not recorded 23(67.6%) 42(72.4%)   
   
  
Sputum
‡
 n=47 n=87   
Positive 6(12.8%) 24(27.6%) 0.29(0.10 -0.86) 0.025 
Negative 21(44.7%) 25(28.7%)   
Not recorded 20(42.5%) 38(43.7%)   
   
  
CT brain findings n= 19 n = 55   
Hydrocephalus 
  
    
Yes 5(26.3%) 27(49.1%) 0.37(0.11-1.16) 0.096 
     
Tuberculoma         
Yes 4(21.0%) 14(25.4%) 0.97(0.27-3.39) 0.963 
     
Basal enhancement         
Yes 3(15.7%) 19(34.5%) 0.35(0.09-1.37) 0.133 
     
Evidence of Infarct         
Yes 1(5.2%) 9(16.3%) 0.28(0.03-2.40) 0.248 
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3.7 Cerebrospinal Fluid Count in children with TBM 
Although the CSF biochemistry showed no difference between HIV-infected and -
uninfected children, the median protein level was elevated  (>0.5g/dl) in both groups  
(Table 12). CSF glucose levels were similar in both groups. A higher lymphocyte count 
was noted among HIV-uninfected children compared to HIV-infected children, but this 
was not statistically significant. ADA was requested on 93 of the 143 (65.0%) of 
children, of whom 19 (20.4%) had levels above 8.0µ/L (Table 12).
 42 
 
Table 12:Cerebrospinal fluid (CSF) biochemistry results comparing HIV-infected to 
-uninfected children 
 
 
 
 
 
 
 
 
 
 CSF Biochemistry 
results 
HIV-infected HIV-uninfected p-value 
CSF protein (g/dl) n = 46 n = 82  
Median 0.935 1.03 0.990 
Range 0.02-7.5 0.1-6.9  
   
 
Chloride (mmol/l) n=46 n = 81  
Median 117 117 0.354 
Range 61-130 87-134  
   
 
Glucose (mmol/l) n =  46 n = 82  
Median 2.4 2.6 0.704 
Range 0-5.8 0.3-6.1  
   
 
Polymorphs (cu/mm) 46 82  
Median 2 5.5 0.622 
Range 0-1000 0-10001  
   
 
Lymphocytes (cu/mm) n = 46 n = 82  
Median 12 20.5 0.400 
Range 0-416 0-1490  
 
  
 
ADA (U/l) n=47 n=87  
<8.0 33 42 0.291 
>/=8.0 6 12  
Not recorded 8 33  
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3.8 Outcomes in children with TBM 
Neurological outcomes were analysed in 134 children. Outcomes were recorded on 
discharge only (there was no long term follow-up) as “demised or “neurological 
sequelae” (i.e. neurological abnormality not previously present), which was further 
subdivided into “returned to baseline function” (returned to function prior to the onset of 
TBM) or “not back to baseline function”. These findings were based on the attending-
physician recorded findings (Table 13). In hospital case fatality rates were similar 
between HIV-infected (6.4%) and -uninfected children (6.9%). Of those discharged, 
33% (26/79) of HIV-uninfected children and 22.7% (10/ 44) of HIV-infected had 
neurological sequelae. Neurological assessments were unavailable in 16/44 (36.4%) 
and 30/79 (37.9%) of HIV-infected and HIV-uninfected children, respectively, due to 
missing or incomplete medical record documentation (Table13). There were no 
difference in outcomes in HIV-infected and -uninfected children when TBM cases were 
stratified as “confirmed and probable” or “possible” TBM (Table 14). 
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Table 13: Outcomes of children admitted with Tuberculosis meningitis (TBM) 
 
 
 
 
 
 
 
 
 
*CFR: case fatality rate 
ºBaseline function: Back to level of function before hospitalisation with TBM 
+Not back to baseline function: Had some neurological deficit after hospitalisation with TBM 
 
 
 
Table 14: Children who demised or were discharged stratified as “confirmed and 
probable” or “possible” or “Undefined” 
 
 
 
 
 
 
 
 
 
 
 
HIV-infected HIV-uninfected 
 
 
n=47 n=87 
Demised (CFR%)* 3(6.4%) 6(6.9%) 
Discharged 44(93.6%) 79(90.8%) 
Not recorded 0 2(2.3%) 
Neurological sequelae among 
survivors: 
  
-Back to baseline º 18/44(40.9%) 25/79(31.6%) 
-Not back to baseline+  10/44(22.7%) 26/79(33.0%) 
-Baseline status not recorded or 
medical record  unavailable 
16/44(36.4%) 28/79(35.4%) 
 
HIV-Infected HIV-Uninfected p-value 
Demised n=3 n=6  
Confirmed and probable 2 3 0.850 
Possible 1 2  
Undefined 0 1  
Discharged n=44 n=79  
Confirmed and probable 19 27 0.692 
Possible 16 27  
Undefined 9 24  
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4.0 Discussion 
The burden of TBM in our setting was greater in HIV-infected compared to -uninfected 
children. Overall, the incidence of TBM increased until 2009, following which we 
observed reduction from 2010 onward.  Although the HAART coverage improved in 
HIV-infected children, no substantial effect was noticed on the burden of TBM in HIV-
infected children up to 2009, however, the majority of cases occurred in the severely 
immunocompromised children. This was supported by a study conducted in the same 
setting between 2005 and 2009, which demonstrated no significant change in the 
number of cases of overall EPTB as HAART coverage increased (60). A decline in TBM 
was noted after 2009, which could have been from strengthening of the HAART 
programme and immune reconstitution among those who had been previously initiated 
on HAART. Furthermore, the decline in TBM from 2010 may also be due to a decrease 
in TB amongst adults in this endemic HIV/TB setting, which could have resulted from 
HIV-infected adults accessing HAART that resulted in reduced incidence of TB and 
consequently reduction in transmission of MTB to susceptible children in the 
community. However, adult TB patients with advanced AIDS (CD4 <200) have been 
shown to be less infectious than those with early disease (61). Furthermore, 
improvements in case findings, contact tracing, strengthening of TB programs, 
increased awareness and improved management of HIV-infected children with respect 
to nutrition, earlier detection of illnesses can also account for reduced transmission 
rates. The burden of disease was predominantly in children under 1 year of age where a 
more significant decline in the incidence of TBM was noted in 2010 and 2011. This 
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further highlights the effect of the various interventions such as HAART and PMTCT on 
the most vulnerable age group.  
 
When we classified TBM as “confirmed and probable” to determine the effect on the 
cases of TBM that were diagnosed using a definitive outcome measure, we observed a 
more substantial reduction in the cases of TBM (62.1%; 95% CI: 22.43-81.46; p- 
value=0.005) comparing the period 2006-2009 with 2010-2011, including in HIV-infected 
and -uninfected children.  
 
Clinical findings in children with TBM 
In our study we observed a significant difference in the median age comparing HIV-
infected (7.71 years) to -uninfected children (2.75 years), p<0.0001. In contrast, other 
paediatric studies reported similar ages between HIV-infected and -uninfected children 
(22,23,28). This may be explained in our setting by a failure to initiate HAART in HIV-
infected children early in the course of their illness as HIV testing guidelines for infants 
were not well implemented over the earlier study years. In addition, 69.8% of children 
had severe immunological suppression by the time TBM was diagnosed.  
 
A previous history of TB was more common in HIV-infected children (32.4%) compared 
to HIV-uninfected children (8.6%). It was not known if patients in the study, with 
previous TB, completed TB treatment or if they were compliant. These findings are 
nonetheless similar to other paediatric studies (30% versus 9%) (23) . Furthermore, 
38.2% of HIV-infected and 22.4% of -uninfected children reported a contact with proven 
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pulmonary TB within the household. This emphasises the importance of screening 
adults and treating household contacts in order to limit the spread of infection to children 
(50). Additionally, instituting INH prophylaxis in HIV-infected children has been shown to 
reduce the incidence of TB by 72% regardless of whether the child was on HAART or 
not (62).  
 
The clinical features typical of PTB such as coughing, fever, weight loss and night 
sweats showed no significant  difference between HIV-infected  and -uninfected children 
in this study, which is in keeping with findings reported in previous paediatric and adult 
studies (10,22,23,43). However, coughing was present in approximately 50% of both 
HIV-infected and -uninfected children which may suggest that these children often have 
symptoms of a cough from pulmonary TB prior to subsequent dissemination to the 
brain. Symptoms such as fever and neck pain, although thought to be findings of acute 
bacterial meningitis were also commonly found in children with TBM. Thus a child who 
fails to culture an organism or to respond to conventional antibiotics after an admission 
for suspected bacterial meningitis should be considered as possibly having TBM . 
Seizures were noted to be the most common sign amongst all children treated for TBM. 
The pathological mechanism as to why such a high proportion present with seizures 
could be related to increased intracranial pressure as a complication of the meningitis 
(17). 
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Investigations in children with TBM 
We observed no significant difference in CSF biochemistry and cell counts between 
HIV-infected and -uninfected children.  The typical CSF biochemistry of TBM, as 
similarly reported, showed a lymphocyte predominance, high protein and low glucose 
(50). These children are often misdiagnosed and treated for acute bacterial meningitis 
based on the initial neutrophil predominance (27,47,50). This further highlights the need 
to consider TBM in children failing to respond to conventional antibiotics and the 
importance of serial lumbar punctures to diagnose TBM.   
 
Positive bacteriological culture of MTB on CSF was identified in only 5.6% of children 
compared to other paediatric studies which reported rates of 30% and 37% (24,25). 
CSF cultures were, however, only requested in 35% of patients, partly because 
clinicians in this setting do not routinely request MTB culture on CSF specimens due to 
its perceived low sensitivity for culture. Serial lumbar punctures may prove valuable as 
they increase the likelihood of AFB positive smears (from 39% to 87%) and positive TB 
cultures on CSF (from52% to 83%) in children (17,24). Furthermore, the yield of 
detecting a positive AFB (acid fast bacilli stain) may be improved by centrifuging 10-20 
millilitres of CSF, prior to the preparation of the smear; which is not routinely done in 
children in our setting. 
 
 The British Infection Society guidelines do not recommend CSF ADA in children and 
adults as a routine test for TBM (64). This is in contrast to another paediatric study that 
showed that CSF ADA was a useful test for the rapid diagnosis of TBM (65). We found 
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that CSF ADA was not useful for diagnosing of TBM among children in our setting, as 
did an adult study that demonstrated limited value in HIV-infected patients (63). 
 
The tuberculin skin test was positive in 32.8% of HIV-uninfected children and 11.1% of 
HIV-infected children which was similarly reported in three paediatric studies. However, 
Van der Wreet and Topley et. al. (22,23) recorded a positive tuberculin skin test in as 
many as 30%-45% of HIV-infected children, almost triple to what our study 
demonstrated. Our study did not demonstrate this, probably as a large number of 
children did not have documented tuberculin skin test (TST) results.  
 
Radiological tests can assist with the diagnosis of TBM as characteristic features may 
be present on a CT scan (21). However, hydrocephalus, basal enhancement, infarction 
and tuberculomas were less commonly noted among HIV-infected children in this study, 
but failed to reach statistical significance. Overall, hydrocephalus and basal 
enhancement were found in 26.3% of HIV-infected versus 49.1% of HIV-uninfected 
children and 15.7% in HIV-infected versus 34.5% HIV-uninfected of children, 
respectively. These findings were lower compared to other paediatric studies that 
demonstrated hydrocephalus in 72% and 97.7% of HIV-infected and -uninfected 
children respectively (23), and basal enhancement in 40% of HIV-infected and 53% of 
HIV-uninfected children (22).  
 
Diagnosis of TB could be improved by the Line probe assay and XpertTm.  The line 
probe assay identifies DNA specific to MTB on smear positive sputum or on a cultured 
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MTB isolate. It also identifies isoniazid, rifampacin, fluoroquinolones and 
aminoglycoside susceptibility. It requires sophisticated laboratory equipment and it has 
not yet been approved by WHO as an initial diagnostic test. The XpertTm  is a cartridge-
based automated PCR test that detects MTB and rifampacin susceptibility on gastric 
aspirated and sputum. It has a turnaround time of 2 hours and a high sensitivity. It is 
currently being validated for other clinical specimens (66). 
 
Mortality and morbidity in children with TBM 
The mortality from TBM with adequate therapy has been reported as 10-20% in 
developed and 30-40% in developing countries (17). We reported a mortality of about 
6% in both HIV-infected and -uninfected children in this setting. A high index of 
suspicion and early initiation of TBM treatment by clinicians in our setting could account 
for a lower mortality. Morbidity, only neurological, was based on short-term outcomes 
only (i.e. prior to discharge) and found to be higher in HIV-uninfected children (33%) 
compared to HIV-infected children (22.7%), however, baseline statuses of all children 
were not known. When comparing this to the other paediatric studies; no differences in 
morbidity between HIV-infected and HIV-uninfected children was reported (22,23,28). 
 
 
 
 
 
 
 51 
 
5.0 Limitations 
Several limitations were encountered in this study. This was a retrospective study and 
approximately 33% of the clinical and/or laboratory data was unavailable in children due 
to patient records being unavailable. Furthermore, there was a lack of standard history-
taking; including, HIV statuses not obtained on all children, compliance with treatment in 
patients previously treated with TB, opening pressures of LP’s (lumbar punctures) and 
no long term follow up of all patients discharged with TBM. Also, in HIV-infected 
children, treatment regimens, CD4 and viral loads were not always obtained. 
Furthermore, we were unable to classify TBM as confirmed, probable or possible in 
28% of our cases as data was unavailable. Computed tomography scan results were 
not always documented and physicians may have not always recorded negative 
findings. Another limitation to this study was that we used population estimates as our 
denominator for this study, however, this was consistent over the study period. The 
prevalence of HIV in the study was calculated based on models from the Actuarial 
Society of South Africa and these models may have not accurately accounted for 
improvements in the PMTCT programme.  
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6.0 Conclusions 
The incidence of TBM has decreased across the study period 2006-2011 but 
particularly from 2010.The majority of children in the study were HIV-uninfected who 
were younger at the time of presentation. Clinical features of TBM were non-specific but 
noted to be similar for HIV-infected and -uninfected children. Diagnosing TB in children 
offers huge challenges, particularly in HIV-infected children. In addition, CSF and CTB 
findings of TBM are less specific in HIV-infected children. Although we have shown a 
decline in incidence of TBM in HIV-infected and HIV-uninfected children in our setting, 
we believe that our study likely underestimated the incidence of TBM in this population 
and a high index of suspicion needs to be maintained when treating children for 
meningitis in high TB/HIV settings.  
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7.0 Recommendations 
This study provides valuable information regarding the incidence of TBM. A prospective 
study would be beneficial to evaluate the long-term neurological outcomes of children 
with TBM. Our strongest recommendation would be that clinicians send TB cultures on 
all CSF samples. Furthermore, clinicians should avoid requesting ADA’s on children as 
this test lacks sensitivity and specificity. Unquestionably, more research needs to be 
targeted at finding an improved vaccine to replace or augment the current BCG vaccine. 
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